NeuroBo Pharma Files Routine 8-K on Feb 1, No New Material Events
Ticker: MTVA · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, routine-filing, disclosure
TL;DR
**NeuroBo filed a routine 8-K, nothing major to see here.**
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on February 1, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard, routine corporate disclosures without specific new material events like acquisitions or major financial changes. For investors, this means there's no immediate new information that would drastically alter the company's valuation or outlook, suggesting a period of operational stability or a lack of significant recent developments.
Why It Matters
This filing is a standard disclosure, indicating no major new developments that would immediately impact NeuroBo Pharmaceuticals' stock price or strategic direction. It suggests business as usual for the company.
Risk Assessment
Risk Level: low — This 8-K is a standard, informational filing and does not introduce new risks or significant changes to the company's operations or financial health.
Analyst Insight
A smart investor would note this as a routine filing, indicating no immediate catalysts or red flags. Further due diligence would focus on the company's core business, clinical trial progress, and financial health, as this filing provides no new material information.
Key Numbers
- 001-37809 — Commission File Number (identifies NeuroBo Pharmaceuticals, Inc. with the SEC)
- 47-2389984 — IRS Employer Identification No. (identifies NeuroBo Pharmaceuticals, Inc. for tax purposes)
- $0.001 — par value per share (par value of NeuroBo Pharmaceuticals, Inc. Common Stock)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for NeuroBo Pharmaceuticals, Inc.
- 001-37809 (dollar_amount) — Commission File Number for NeuroBo Pharmaceuticals, Inc.
- NRBO (company) — trading symbol for NeuroBo Pharmaceuticals, Inc. Common Stock
- The Nasdaq Stock Market LLC (company) — exchange where NeuroBo Pharmaceuticals, Inc. Common Stock is registered
FAQ
What is the primary purpose of this 8-K filing by NeuroBo Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated February 1, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits,' which are standard categories for disclosing various corporate activities or attachments.
What is the trading symbol and the exchange where NeuroBo Pharmaceuticals, Inc.'s common stock is registered?
NeuroBo Pharmaceuticals, Inc.'s common stock trades under the symbol 'NRBO' and is registered on The Nasdaq Stock Market LLC.
What is the state of incorporation for NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. is incorporated in Delaware, as stated in the filing.
Does this 8-K filing indicate any specific new material events like an acquisition or a major financial transaction?
No, this 8-K filing does not specify any new material events such as an acquisition, a major financial transaction, or significant operational changes. It broadly covers 'Other Events' and 'Financial Statements and Exhibits' without detailing specific impactful news.
What was the former name of NeuroBo Pharmaceuticals, Inc. and when did the name change occur?
The former name of NeuroBo Pharmaceuticals, Inc. was Gemphire Therapeutics Inc., and the name change occurred on March 31, 2015.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-02-01 08:30:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240201x8k.htm (8-K) — 42KB
- nrbo-20240201xex99d1.htm (EX-99.1) — 18KB
- nrbo-20240201x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240201xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-000684.txt ( ) — 230KB
- nrbo-20240201.xsd (EX-101.SCH) — 3KB
- nrbo-20240201_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240201_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240201x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On February 1 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated February 1, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: February 1, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer